Lot-release criteria, postlicensure quality control, and the Haemophilus influenzae type b conjugate vaccines.
Egan
W
W
Frasch
C E
CE
Anthony
B F
BF
D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology / Q000592:standards*; D001426:Bacterial Proteins / Q000276:immunology / Q000592:standards*; D004345:Drug Industry / Q000592:standards*; D018073:Haemophilus Vaccines / Q000276:immunology / Q000592:standards*; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000276:immunology; D011786:Quality Control; D018074:Vaccines, Conjugate / Q000276:immunology / Q000592:standards*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000592:standards*
D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C061963:HibTITER protein, Haemophilus influenzae